{"medicine":"Osimertinib","products":[{"brand":"Tagrisso","holder":"AstraZeneca AB","atc":"L01EB04","target":"EGFR tyrosine kinase inhibitor","mechanism":"Osimertinib is an irreversible inhibitor of epidermal growth factor receptors (EGFR) harboring sensitising mutations and the T790M resistance mutation.","authorised":"2016-02-01","label_updated":"2026-08-18","conditional_approval":false,"orphan":false,"smpc_en":"https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf","smpc_de":"https://www.ema.europa.eu/de/documents/product-information/tagrisso-epar-product-information_de.pdf","epar":"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso","biosimilars_and_generics":[]}],"total":5,"indications":[{"id":"6772c64cec6d4d1e","medicine":"Osimertinib (Tagrisso)","tumour":"Non-small cell lung cancer","histology":null,"setting":"Adjuvant","requirement":"EGFR exon 19 deletions or exon 21 (L858R)","biomarker_must_be_absent":false,"other_biomarkers":[],"regimen":"Monotherapy","conditions":"After complete tumour resection; Stage IB-IIIA","conditional_approval":false,"needs_review":false,"link":"https://oncolabels.com/?open=6772c64cec6d4d1e"},{"id":"2c4089169d98021b","medicine":"Osimertinib (Tagrisso)","tumour":"Non-small cell lung cancer","histology":null,"setting":"1st line, advanced","requirement":"EGFR mutation","biomarker_must_be_absent":false,"other_biomarkers":[],"regimen":"Monotherapy","conditions":null,"conditional_approval":false,"needs_review":false,"link":"https://oncolabels.com/?open=2c4089169d98021b"},{"id":"1acae0b2aa6c43c1","medicine":"Osimertinib (Tagrisso)","tumour":"Non-small cell lung cancer","histology":null,"setting":"1st line, advanced","requirement":"EGFR exon 19 deletions or exon 21 (L858R)","biomarker_must_be_absent":false,"other_biomarkers":[],"regimen":"+ pemetrexed and platinum-based chemotherapy","conditions":null,"conditional_approval":false,"needs_review":false,"link":"https://oncolabels.com/?open=1acae0b2aa6c43c1"},{"id":"84c9f1eceebea66c","medicine":"Osimertinib (Tagrisso)","tumour":"Non-small cell lung cancer","histology":null,"setting":"Consolidation, locally advanced","requirement":"EGFR exon 19 deletions or exon 21 (L858R)","biomarker_must_be_absent":false,"other_biomarkers":[],"regimen":"Monotherapy","conditions":"After platinum-based chemoradiation therapy without disease progression; Unresectable; disease has not progressed during or following platinum-based chemoradiation therapy","conditional_approval":false,"needs_review":false,"link":"https://oncolabels.com/?open=84c9f1eceebea66c"},{"id":"4aed1b98cb4921af","medicine":"Osimertinib (Tagrisso)","tumour":"Non-small cell lung cancer","histology":null,"setting":"Advanced","requirement":"EGFR T790M","biomarker_must_be_absent":false,"other_biomarkers":[],"regimen":"Monotherapy","conditions":null,"conditional_approval":false,"needs_review":false,"link":"https://oncolabels.com/?open=4aed1b98cb4921af"}],"dataset":{"version":"52f637a50d","ema_data_of":"2026-11-05","checked":"2026-11-05","notice":"EU label indications from EMA product information (SmPC section 4.1), generated by AI and not reviewed by a person. A non-commercial reference for education and research, not medical advice; the current SmPC takes precedence."}}